Bayer ‘deeply suspicious’ of pre-trial discovery bid in fight over Xarelto patents

Ashurst 2023-03-23 2:09 pm By Sam Matthews | Melbourne

Please login to bookmark

German pharmaceutical giant Bayer has slammed generic drug make Sandoz’s late bid for documents, which it called an attempt to “divert and distract” Bayer on the eve of a three-week trial over the patents for its top-selling blood clot drug Xarelto.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au